GlassScriptPhysician profile
Sonya A Tanna
NPI 1316246424
$14,925.62
in general payments reported to CMS, 2019-2025
29 companies · $3,083 in 2025
The $3,083 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,612 · 2022: $2,774 · 2023: $3,415 · 2024: $3,042 · 2025: $3,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,531 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,531.21 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,216.58 | 2021-2025 | |
| Genzyme Corporation | $1,573.53 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,231.59 | 2021-2025 | |
| Galderma Laboratories, L.P. | $1,075.13 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Janssen Biotech, INC. | $1,010.19 | 2021-2025 | Tremfya, Stelara, Simponi |
| Dermavant Sciences, INC. | $836.79 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $821.28 | 2021-2025 | Blu-U, Odomzo, Winlevi |
| Regeneron Healthcare Solutions, INC. | $713.21 | 2021-2025 | Dupixent |
| Ucb, INC. | $655.25 | 2021-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $653.09 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Arcutis Biotherapeutics, INC. | $643.36 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $532.66 | 2022-2025 | Sotyktu |
| Mayne Pharma Commercial LLC | $461.91 | 2021-2025 | |
| Leo Pharma INC. | $364.12 | 2021-2025 | Adbry, Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $330.23 | 2021-2025 | Cabtreo, Arazlo, Jublia |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $326.87 | 2021-2025 | Otezla, Otezla |
| Incyte Corporation | $306.20 | 2021-2025 | Opzelura |
| Pfizer INC. | $271.98 | 2021-2025 | |
| Revance Therapeutics, INC. | $194.95 | 2024-2025 | Daxxify |
| Almirall LLC | $185.64 | 2021-2025 | Klisyri |
| Journey Medical Corporation | $152.46 | 2022-2023 | |
| Organon LLC | $90.13 | 2025 | Vtama |
| Biofrontera INC. | $86.56 | 2022-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Vyne Pharmaceuticals INC. | $72.89 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $37.37 | 2021 | |
| Merz North America, INC. | $27.76 | 2025 | |
| Boston Scientific Corporation | $19.15 | 2024 | Varithena Administration Pack |
| Botanix Sb INC | $18.95 | 2025 | Sofdra |
| Genentech USA, INC. | $15.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonya Tanna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.